Christopher Morabito - 19 Jan 2022 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Role
Chief Medical Officer
Signature
/s/ Peter Thomson, as attorney-in-fact for Christopher Morabito
Issuer symbol
FULC
Transactions as of
19 Jan 2022
Net transactions value
$0
Form type
4
Filing time
21 Jan 2022, 15:15:17 UTC
Previous filing
29 Jun 2021
Next filing
15 Jul 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FULC Stock Option (right to buy) Award $0 +59,744 $0.000000 59,744 19 Jan 2022 Common Stock 59,744 $12.69 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on January 19, 2022 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2022, subject to continued service.